気になる企業 – AMGEN – オリジナルのmAb/BiTE antibody – Biosimilarも手がけるBiologicsの雄 – ID18102 [2020/06/24] ID18102

AMGEN

独自技術

  • BiTE (Bispecific T cell Engager) antibody

売上規模

2019年の売り上げ。

  • 2019年売り上げ 約2.3兆円
  • BEVENITY (romosozumab-aqqg)の売り上げは、約189億円
  • AMGEVITA (adalimumab)の売り上げは、約215億円
  • KANJINTI (trastuzumab-anns)の売り上げは、226億円

AMGEN Press Release
Amgen Reports Fourth Quarter And Full Year 2019 Financial Results, AMGEN – サイトより

http://investors.amgen.com/news-releases/news-release-details/amgen-reports-fourth-quarter-and-full-year-2019-financial/

Product Pipeline

  • AIMOVIG (erenumab-aooe)
    • Therapeutic Area : Neuroscience
    • Modality : mAb
    • Target : CGRP-R (calcitonin gene-related peptide receptor)
    • Initial U.S. Approval: 2018
    • 70mg/month
  • PROLIA (denosumab)
    • Therapeutic Area : Bone
    • Modality : mAb
    • Initial U.S. Approval : 2010
  • REPATHA (evolocumab)
    • Therapeutic Area : Cardiovascular
    • Modality : mAb
    • Initial U.S. Approval : 2015
  • TEZEPELUMAB
    • Therapeutic Area : Inflammation
    • Modality : mAb
  • ABP 798 (biosimilar rituximab)
    • Therapeutic Area : Hematology / Oncology
    • Moality : mAb
  • ABP 959 (Biosimilar eculizumab)
    • Therapeutic Area : Hematology / Oncology
    • Modality : mAb
  • BLINCYTO (blinatumomab)
    • Therapeutic Area : Hematology / Oncology
    • Modality : BiTE Ab
    • Target : CD-19 x CD3 BiTE
    • Initial U.S. Approval: 2014
    • 20mg/maximum
  • その他 BiTE Antibody : 11 products
  • EVENITY (romosazumab-aqqg)
    • Therapeutic Area : Bone
    • Modality : mAb
    • Target : sclerostin
    • Initial U.S. Approval : 2019
    • 210mg/month
  • AMG 714/PrV-015
    • Therapeutic Area : Inflammation
    • Modality : mAb
  • AMG 404
    • Therapeutic Area : Hematology / Oncology
    • Modality : mAb
  • AMG 430
    • Therapeutic Area : Infalmmation
    • Modality : mAb
  • IMLYGIC (talimogene Laherparepvec)
    • Therapeutic Area : Hematology / Oncology
    • Modality : Oncolytic Immunotherapy
    • Target : HSV-1 vector with KEYTRUDA (Anti PD-1, Merck & Company)
    • Initial U.S. Approval : 2015
    • 1e6 PFU/mL x 4mL, subsequent: 1e8 PFU/mL x 4mL
  • CAR T
    • AMG 119
      • Therapeutic Area : Hematology / Oncology
      • Modality : CAR T
  • Small Molecule
    • KYPROLIS
    • OMECAMTIV MECARBIL
    • OTEZLA
    • AMG 510
    • AMG 199
    • AMG 397
    • AMG 594
  • Peptibody
    • NPLATE (romiplostim)
    • PARSABIV (etelcalcetide)
  • Bispecific Antibody
    • ROZIBAFUSP ALFA
  • Fusion Protein
    • AMG 171
  • XmAb Antiboldy
    • AMG 424
  • DARPin protein
    • AMG 506
  • siRNA
    • AMG 890
      • Therapeutic Area : Cardiovascular
      • Modality : mAb

AMGEN

PIPELINE 2020/06

https://www.amgenpipeline.com
編集履歴
2020/06/19 はりきり(MR)
2020/06/24 追加(RocheのBiosimilar戦略, 2015版)

Biosimilar

PfizerのBiosimilarの売り上げは、約319億円(2016)から約1,000億円(2020)に伸長し、その後、2027には、6,000億円を見込むForbes

  • AMJEVITA (adalimumab-atto), injection (40mg/0.8mL, 20mg/0.4mL)
    • Initial U.S. Approval: 2016
  • AVSOLA (infliximab-axxq), injection (100mg/vial)
    • Initial U.S. Approval: 2019
  • KANJINTI (trastumumab-anns), injection (420mg/vial)
    • Initial U.S. Approval: 2019
  • MVASI (bevacizumab-awwb), injection (100mg/vial, 400mg/vial)
    • Initial U.S. Approval: 2017)

FDA-Approved Biosimilar Products

AMGEN サイト – より

https://www.amgenbiosimilars.com/products/approved-products/